<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shinde, Popat D.</style></author><author><style face="normal" font="default" size="100%">Jadhav, Vinod H.</style></author><author><style face="normal" font="default" size="100%">Borate, Hanumant B.</style></author><author><style face="normal" font="default" size="100%">Bhide, Sunil R.</style></author><author><style face="normal" font="default" size="100%">Sonawane, Kiran B.</style></author><author><style face="normal" font="default" size="100%">Wakharkar, Radhika D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Enantiomeric separation of novel anticancer agent 5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en- 1-one</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Chromatography A</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anticancer</style></keyword><keyword><style  face="normal" font="default" size="100%">column chromatography</style></keyword><keyword><style  face="normal" font="default" size="100%">diaryl cyclopentenone</style></keyword><keyword><style  face="normal" font="default" size="100%">diastereoisomers</style></keyword><keyword><style  face="normal" font="default" size="100%">enantioseparation</style></keyword><keyword><style  face="normal" font="default" size="100%">HPLC</style></keyword><keyword><style  face="normal" font="default" size="100%">Resolution</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JAN</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1-2</style></number><publisher><style face="normal" font="default" size="100%">ELSEVIER SCIENCE BV</style></publisher><pub-location><style face="normal" font="default" size="100%">PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS</style></pub-location><volume><style face="normal" font="default" size="100%">1138</style></volume><pages><style face="normal" font="default" size="100%">184-189</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The enantiomers of 5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en- 1-one, a novel anticancer agent, were separated by derivatisation with caronaldehyde, separation of the resulting diastereoisomers of the corresponding esters by silica gel column chromatography and regeneration of alcohols (S)-5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2 -en-1-one and (R)5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2- en- 1-one under aqueous conditions. The absolute configuration of the enantiomers was determined by H-1 NMR studies of the corresponding Mosher esters. Alternatively, the enantiomers were separated by preparative HPLC to collect the (S)- and (R)-5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2 -en-1-ones with high purity which was comparable with that obtained by the chemical method. The details of these methods have been presented herein. (c) 2006 Elsevier B.V. All rights reserved.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1-2</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">3.926</style></custom4></record></records></xml>